Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 625 of 672 entries
View as:

Peripheral Body Fat Distribution After Switching Zidovudine and Lamivudine to Truvada

Phase: N/A Priority: Normal
NCT ID: NCT00324649 Org: User:
Start: 05/31/06 End: 09/30/08 Due: 09/30/09

Study of Veltuzumab and 90Y-Epratuzumab in Relapsed/Refractory, Aggressive NHL

Phase: N/A Priority: Normal
NCT ID: NCT01101581 Org: User:
Start: 05/31/10 End: 03/31/17 Due: 03/31/18

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT05382286 Org: User:
Start: 07/25/22 End: 02/28/27 Due: 02/28/28

A Gilead Sequence Registry of Subjects Who Did Not Achieve Sustained Virologic Response

Phase: N/A Priority: Normal
NCT ID: NCT01457768 Org: User:
Start: 12/19/11 End: 04/09/18 Due: 04/09/19

SWEET: Once Daily Truvada Versus Twice Daily Combivir for the Treatment of HIV Infection

Phase: N/A Priority: Normal
NCT ID: NCT00323544 Org: User:
Start: 10/31/04 End: 10/31/07 Due: 10/31/08

Use-Results Surveillance Study of Harvoni® in Japanese Patients With Chronic Genotype 1 Hepatitis C Virus Infection

Phase: N/A Priority: Normal
NCT ID: NCT02591277 Org: User:
Start: 11/30/15 End: 11/01/17 Due: 11/01/18

Sofosbuvir With Peginterferon Alfa 2a and Ribavirin for 12 Weeks in Treatment-Naive Subjects With Chronic Genotype 1, 4, 5, or 6 HCV Infection

Phase: N/A Priority: Normal
NCT ID: NCT01641640 Org: User:
Start: 06/30/12 End: 04/30/13 Due: 04/30/14

Effect of Eleclazine (GS-6615) on Exercise Capacity in Subjects With Symptomatic Hypertrophic Cardiomyopathy

Phase: N/A Priority: Normal
NCT ID: NCT02291237 Org: User:
Start: 02/05/15 End: 02/17/17 Due: 02/17/18

Part A: Drug Interaction Study of Sofosbuvir and Antiretroviral Therapy (ART) Combinations in HIV and Hepatitis C Virus (HCV) Co-infected Patients. Part B: Efficacy and Safety of Sofosbuvir for 12 Weeks in HIV/HCV Co-infected Patients.

Phase: N/A Priority: Normal
NCT ID: NCT01565889 Org: User:
Start: 03/31/12 End: 11/30/13 Due: 11/30/14

Study of Magrolimab in Combination With Azacitidine Versus Physician's Choice of Venetoclax in Combination With Azacitidine or Intensive Chemotherapy in Patients With TP53 Mutant Acute Myeloid Leukemia That Have Not Been Treated

Phase: N/A Priority: Normal
NCT ID: NCT04778397 Org: User:
Start: 07/01/21 End: 03/25/24 Due: 03/25/25

Efficacy and Safety of Oral Regimens for the Treatment of Chronic HCV Infection

Phase: N/A Priority: Normal
NCT ID: NCT02202980 Org: User:
Start: 08/04/14 End: 05/09/16 Due: 05/09/17

Aztreonam for Inhalation Solution vs Tobramycin Inhalation Solution in Patients With Cystic Fibrosis & Pseudomonas Aeruginosa

Phase: N/A Priority: Normal
NCT ID: NCT00757237 Org: User:
Start: 08/31/08 End: 11/30/10 Due: 11/30/11

Observational Study of the Durability of Seroconversion Chronic HBV Patients Who Seroconverted in a Previous Gilead-Sponsored Study of ADV.

Phase: N/A Priority: Normal
NCT ID: NCT00158717 Org: User:
Start: 04/30/03 End: 04/30/06 Due: 04/30/07

A Trial of GS-9219 in Chronic Lymphocytic Leukemia (CLL), Non-Hodgkin's Lymphoma (NHL) or Multiple Myeloma (MM)

Phase: N/A Priority: Normal
NCT ID: NCT00499239 Org: User:
Start: 07/31/07 End: 10/31/10 Due: 10/31/11

Effect of Eleclazine on Shortening of the QT Interval, Safety, and Tolerability in Adults With Long QT Syndrome Type 3

Phase: N/A Priority: Normal
NCT ID: NCT02300558 Org: User:
Start: 12/17/14 End: 02/15/17 Due: 02/15/18

Study of Edecesertib in Participants With Cutaneous Lupus Erythematosus (CLE)

Phase: N/A Priority: Normal
NCT ID: NCT05629208 Org: User:
Start: 04/17/23 End: 09/30/25 Due: 09/30/26

Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Idelalisib in Adults Receiving Ruxolitinib as Therapy for Primary, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis With Progressive or Relapsed Disease

Phase: N/A Priority: Normal
NCT ID: NCT02436135 Org: User:
Start: 06/05/15 End: 11/20/17 Due: 11/20/18

Study to Evaluate the Efficacy and Safety of Tilpisertib in Adults With Moderately to Severely Active Ulcerative Colitis

Phase: N/A Priority: Normal
NCT ID: NCT04130919 Org: User:
Start: 12/20/19 End: 12/14/21 Due: 12/14/22

A Non-Interventional Pilot Study Assessing Whether Lysyl Oxidase-like 2 (LOXL2) is Present in Subjects With Scleroderma

Phase: N/A Priority: Normal
NCT ID: NCT01881529 Org: User:
Start: 04/30/13 End: 03/31/14 Due: 03/31/15

An Open-Label Study Following Oral Dosing of Seladelpar to Subjects With Primary Biliary Cholangitis (PBC) and Hepatic Impairment (HI)

Phase: N/A Priority: Normal
NCT ID: NCT04950764 Org: User:
Start: 09/17/21 End: 02/27/25 Due: 02/27/26

Ledipasvir/Sofosbuvir Fixed-Dose Combination on Cerebral Metabolism and Neurocognition in Treatment-Naive and Treatment-Experienced Participants With Chronic Genotype 1 HCV Infection

Phase: N/A Priority: Normal
NCT ID: NCT02219685 Org: User:
Start: 08/31/14 End: 04/30/16 Due: 04/30/17

Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 or 24 Weeks in Genotype 1 or 4 HCV Infected Adults With Sickle Cell Disease

Phase: N/A Priority: Normal
NCT ID: NCT02301936 Org: User:
Start: 03/02/15 End: 04/18/16 Due: 04/18/17

Study of Sacituzumab Govitecan in Chinese Patients With Metastatic Triple-negative Breast Cancer Who Received at Least Two Prior Treatments

Phase: N/A Priority: Normal
NCT ID: NCT04454437 Org: User:
Start: 10/23/20 End: 12/31/25 Due: 12/31/26

Study Evaluating the Safety and Efficacy of Islatravir in Combination With Lenacapavir in Virologically Suppressed People With HIV

Phase: N/A Priority: Normal
NCT ID: NCT05052996 Org: User:
Start: 10/05/21 End: 11/30/27 Due: 11/30/28

Study of Obeldesivir in Participants With COVID-19 Who Have a High Risk of Developing Serious or Severe Illness

Phase: N/A Priority: Normal
NCT ID: NCT05603143 Org: User:
Start: 11/05/22 End: 11/07/23 Due: 11/07/24